Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 11/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784735 | 1.00 | TRPM8 (0.42) | TRPM8SLC6A2SLC6A4SLC6A3NR1I2 | |
| SCHEMBL803210 | 0.90 | SLC6A2 (0.39) | TRPM8SLC6A2SLC6A4SLC6A3NR1I2 | |
| SCHEMBL785540 | 0.87 | TRPM8 (0.40) | TRPM8SLC6A2SLC6A4SLC6A3DRD3 | |
| SCHEMBL803262 | 0.87 | TRPM8 (0.40) | TRPM8SLC6A2SLC6A4SLC6A3DRD3 | |
| SCHEMBL785968 | 0.86 | TRPM8 (0.47) | TRPM8NR1I2DRD3NPSR1ADRB1 | |
| SCHEMBL785967 | 0.86 | TRPM8 (0.47) | TRPM8NR1I2DRD3NPSR1ADRB1 | |
| SCHEMBL785744 | 0.84 | SLC6A2 (0.43) | TRPM8SLC6A2SLC6A4SLC6A3DRD3 | |
| SCHEMBL803284 | 0.84 | SLC6A2 (0.43) | TRPM8SLC6A2SLC6A4SLC6A3DRD3 | |
| SCHEMBL784897 | 0.83 | TRPM8 (0.47) | TRPM8SLC6A2SLC6A4SLC6A3NR1I2 | |
| SCHEMBL803263 | 0.83 | TRPM8 (0.47) | TRPM8SLC6A2SLC6A4SLC6A3NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | TRPM8 180/4885SLC6A2 1966/4885SLC6A4 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.